Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px
Document › Details

Applied Biosystems / MDS Sciex. (4/23/07). "Press Release: Applied Biosystems/MDS Sciex Announces New Proteomics Tools for Biomarker Research. New Instrument System and Software Enable More In-depth Study of Emerging Area of Scientific Study". Foster Cit

Organisation Organisation AB Sciex (Applied Biosystems/MDS Sciex joint venture)
  Today AB Sciex LLC
  Group Danaher (Group)
Products Product 4800 Plus MALDI TOF/TOF™ Analyzer
  Product 2 ProteinPilot™ software
Index term Index term Cornell Univ–Applera: mass spectrometer, <200704 supply existent use of ABI/MDS Sciex MS in Alzheimer biomarker study
Persons Person Lauman, Laura (Illumina 201112– VP Marketing before Danaher 201002– President AB SCIEX before PerkinElmer + Waters)
  Person 2 Boorn, Andy (Danaher 201002 President AB SCIEX)
     


Applied Biosystems (NYSE: ABI), an Applera Corporation business, and its joint venture partner, Sciex, a division of MDS Inc.'s Analytical Technologies business, (NYSE:MDZ, TSX:MDS), today announced a new instrument system and software designed to assist the growing number of life scientists involved in biomarker research. An updated release of the Applied Biosystems/MDS SCIEX 4800 MALDI TOF/TOF™ mass spectrometer and enhancements to ProteinPilot™ software, which augments the performance of the 4800 Plus, is expected to help scientists gain deeper quantitative insight into the study of proteomics.

The study of protein biomarkers is important to life scientists because the identification of biomarkers can indicate the presence and progression of a variety of diseases or response to drugs. Central to this research is the science of proteomics through which thousands of proteins in a biological sample - e.g. tissues, cells, serum, urine, cerebrospinal fluid - can be analyzed in the same experiment to obtain a snapshot of the proteome. To discover new biomarker candidates, these snapshots need to be compared quantitatively against other samples, such as healthy versus diseased samples, so the complex differences that exist in biological systems can be found and exploited.

The discovery of protein biomarkers requires large numbers of sample sets and simplified data output produced on proteomics research platforms. Much biomarker research is conducted by biological scientists who are not necessarily proteomics experts. The new advancements from Applied Biosystems/MDS SCIEX are designed to enable non-expert instrument users to achieve higher throughput sample processing, greater depth of proteome coverage, greater statistical rigor, more confident protein detection, and better quantitative results.

Earlier versions of some of these products are helping translational medicine researchers at Cornell University complete a biomarker study of Alzheimer's disease. Utilizing proteomics products from Applied Biosystems/MDS SCIEX, the study identified 23 biomarker candidates that were associated with the presence of Alzheimer's disease and may provide links to the pathological mechanisms of the disease. The scientists involved in the study cited the discovery as a potential breakthrough. Currently, there are no definitive tests available for the diagnosis of the disease in living subjects, with confirmation of its existence normally being made after the death of a patient.

"We set out to better diagnose Alzheimer's disease, and the Applied Biosystems/MDS SCIEX joint venture provided powerful proteomics tools to help identify the biomarker candidates from cerebrospinal fluid," said Kelvin Lee, a Cornell professor of chemical and biomolecular engineering. "Our research uncovered new candidate biomarkers as a first step. The next step in biomarker research is to validate what we found as relevant, so it may someday translate into a real advancement in the medical treatment of Alzheimer's disease."

New Proteomic Tools
The new proteomics tools from Applied Biosystems/MDS SCIEX joint venture include:

- The 4800 Plus MALDI TOF/TOF™ Analyzer - This system is a proteomics analyzer that can identify thousands of proteins in a biological sample. The enhancements from the previous version of the system provide an improved platform to better support the larger sample studies that proteomics researchers are moving towards, especially for biomarker discovery.

- New version of ProteinPilot™ Software -ProteinPilot software is designed to maximize the information that can be obtained from the combination of the 4800 Plus and Applied Biosystems iTRAQ® reagents. It delivers more accurate protein detection, easier manageability and broader support for quantitation, thereby providing greater confidence in the results.

These latest tools are designed to be compatible with the future commercial release of the 8-plex version of Applied Biosystems iTRAQ reagents, a labeling chemistry allowing scientists and biologists to quantitatively compare proteins between samples. The 8-plex version of these reagents is expected to increase the number of samples that can be compared simultaneously, providing higher throughput, better accuracy and greater statistical confidence in research results.

"Biomarker research has the potential to change the face of healthcare," said Laura Lauman, president for Applied Biosystems' proteomics and small molecule division. "The latest enhancements of our portfolio provide powerful tools that deliver higher throughput for analyzing more samples and identifying higher quality biomarker candidates."

The Applied Biosystems/MDS SCIEX Instruments joint venture, which has existed for the past 20 years between Applied Biosystems and MDS Inc., continues to expand its broad portfolio of mass spectrometry-based technologies and systems that enable new advancements in research laboratories in biotechnology, biomedical and pharmaceutical fields.

"Sciex and Applied Biosystems are playing a leadership role in enabling more advanced research by our development of these innovative and reliable tools in the growing area of biomarker research," said Andy Boorn, president for MDS Analytical Technologies. "We are committed to delivering the right combination of instruments and software to help move the biomarker research forward by facilitating the integration of the scientists' efforts."

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.9 billion during fiscal 2006. The Celera Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers. Celera maintains a strategic alliance with Abbott for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera is also discovering and validating therapeutic targets, and it is seeking strategic partnerships to develop therapeutic products based on these discovered targets. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com.

About MDS Inc.

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 6,200 highly skilled people in 28 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

About MDS SCIEX

Sciex is a division of MDS Analytical Technologies. The Sciex product portfolio offers proven market leadership in mass spectrometry through its joint ventures with two of the world's leading analytical instrumentation and life sciences companies, Applied Biosystems, a business of the Applera Corporation and PerkinElmer Inc. Find out more at www.mdssciex.com

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "should," "expect," and "planned," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) rapidly changing technology and dependence on the development and customer acceptance of new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; and (3) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Footnote:
1 A published study in the Annals of Neurology

Applied Biosystems, AB (Design), Applera and Celera are registered trademarks and iTRAQ is a trademark of Applera Corporation or its subsidiaries in the US and/or certain other countries. MALDI TOF/TOF and ProteinPilot are trademarks of Applied Biosystems/MDS SCIEX, a joint venture between Applera Corporation and MDS Inc. Copyright© 2007. Applera Corporation and MDS Inc. All rights reserved.

Notice To Readers: Applied Biosystems' press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.

Applied Biosystems
Media
Anthony Petrucci
508.383.7961

Applera Corporation
Investors
Peter Dworkin
650.554.2479

   
Record changed: 2016-03-19

Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px

More documents for Thermo Fisher (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px